BRIGHTGENE BIO-MEDICAL TEC

Brightgene’s shares stay flat amid a broader decline, but a 52‑week low suggests upside if R&D hits regulatory milestones.

Brightgene Bio‑Medical Tec’s shares fall 12.9%, trading below its 200‑day MA, amid a sector‑wide valuation wobble—key data for investors weighing exit or repositioning.

BrightGene Bio‑Medical Tec (688166.SS) trades flat at CNY 32.07, with a 52‑week high of 72.88. Explore the latest performance, market cap, and peer comparison in our detailed update.